Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
Life of this patent
Estimating the term…
Abstract
Methods of inhibiting a respiratory virus, (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods.
Claims21
1-20. (canceled)
An intranasal composition comprising:
- an antiviral oligonucleotide compound or salt thereof, wherein the oligonucleotide comprises the nucleotide sequence 5′ ATGCTGATCCCTGTC 3′ (SEQ ID NO:508);
- and a pharmaceutically acceptable excipient, carrier, or vehicle.
A method of treating or preventing a viral respiratory infection in a subject, the method comprising administration of a pharmaceutical composition comprising an antiviral oligonucleotide compound or salt thereof, wherein the oligonucleotide comprises the nucleotide sequence 5′ ATGCTGATCCCTGTC 3′ (SEQ ID NO:508);
- and a pharmaceutically acceptable excipient, carrier, or vehicle.
Dependencies are inferred from the claim text.